<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2984">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860414</url>
  </required_header>
  <id_info>
    <org_study_id>JACQUIN 2020</org_study_id>
    <nct_id>NCT04860414</nct_id>
  </id_info>
  <brief_title>Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials.</brief_title>
  <acronym>MAPEG</acronym>
  <official_title>Prospective Monocentric Study of Taste in Patients With Minor or Major Cognitive Disorders Such as Alzheimer's, Through the Analysis of Gustatory Evoked Potentials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 24 million people worldwide suffer from dementia, with Alzheimer's disease&#xD;
      being the most common cause. Alzheimer's disease typically progresses in three stages:&#xD;
      presymptomatic, prodromal (&quot;early onset&quot; or minor cognitive impairment) and major cognitive&#xD;
      impairment with loss of autonomy and significant psycho-behavioral symptoms. Efforts to&#xD;
      counteract its expansion are increasing, and there is a need for biomarkers to identify the&#xD;
      disease in its earliest stage in order to provide prompt treatment.&#xD;
&#xD;
      Faced with a episodic memory disorder, it is possible, thanks to certain criteria,&#xD;
      highlighted by neuroimaging, or by biomarkers obtained by biological analysis of&#xD;
      cerebrospinal fluid (during a lumbar puncture), to detect Alzheimer's disease from the&#xD;
      prodromal stage, or even earlier. The main limitation of these criteria is their invasive&#xD;
      nature. Other non-invasive biomarkers would therefore be useful to help diagnose Alzheimer's&#xD;
      disease at an early stage. Gustatory evoked potentials (GEP), a technique for exploring taste&#xD;
      sensory pathways, could meet these needs.&#xD;
&#xD;
      Indeed, GEPs are a method of exploring the gustatory sensory pathway based on the recording&#xD;
      of cerebral electrical activity by electroencephalography (EEG). It is a painless,&#xD;
      accessible, inexpensive and non-invasive technique. The alteration of gustatory functions is&#xD;
      present in many neurological conditions, but often takes second place to sensory or motor&#xD;
      symptoms. Rare studies have studied taste in patients with Alzheimer's disease, but they have&#xD;
      demonstrated, using subjective tests only, an early gustatory impairment linked to a&#xD;
      degeneration of the gustatory cortex. It was observed that the performance of subjects with&#xD;
      minor or major cognitive impairment was weaker than that of healthy subjects, without the&#xD;
      patient being aware of these taste disorders.&#xD;
&#xD;
      The aim of the study is to explore taste functions in patients with minor cognitive&#xD;
      impairment, major cognitive impairment such as mild Alzheimer's disease, by comparing them to&#xD;
      healthy subjects. For this purpose, we wish to compare the results of subjective taste tests&#xD;
      (tasting solutions, especially salty ones, answering food preference questionnaires),&#xD;
      parameters of taste evoked potentials recorded by electrodes stuck on the scalp and hormonal&#xD;
      parameters obtained by blood sampling, between the three groups of subjects mentioned.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude of gustatory evoked potentials</measure>
    <time_frame>After a fasting period of 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Latency of the gustatory evoked potential</measure>
    <time_frame>After a fasting period of 2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Major Cognitive Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor Cognitive Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Cognitive Impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.</description>
    <arm_group_label>Major Cognitive Impairment</arm_group_label>
    <arm_group_label>Minor Cognitive Impairment</arm_group_label>
    <arm_group_label>No Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale</description>
    <arm_group_label>Major Cognitive Impairment</arm_group_label>
    <arm_group_label>Minor Cognitive Impairment</arm_group_label>
    <arm_group_label>No Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subjective taste tests</intervention_name>
    <description>Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.</description>
    <arm_group_label>Major Cognitive Impairment</arm_group_label>
    <arm_group_label>Minor Cognitive Impairment</arm_group_label>
    <arm_group_label>No Cognitive Impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Objective taste tests</intervention_name>
    <description>Recording of gustatory evoked potentials</description>
    <arm_group_label>Major Cognitive Impairment</arm_group_label>
    <arm_group_label>Minor Cognitive Impairment</arm_group_label>
    <arm_group_label>No Cognitive Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A person who has given oral consent.&#xD;
&#xD;
          -  For patients with early stage Alzheimer's disease, both the primary caregiver and the&#xD;
             patient will need to give oral consent.&#xD;
&#xD;
          -  ADULT&#xD;
&#xD;
          -  Body Mass Index (BMI) &lt; 30 kg/m².&#xD;
&#xD;
          -  Patients meeting the diagnostic criteria for early-stage Alzheimer's disease: imaging&#xD;
             (cerebral MRI), neuropsychobiological criteria (consultation with neuropsychological&#xD;
             assessment, CSF biomarkers) and CDR (Clinical Dementia Rating Scale) rated at 1 or 1.5&#xD;
             - for the &quot;subjects with early-stage Alzheimer's disease&quot; group&#xD;
&#xD;
          -  Patients meeting the diagnostic criteria for minor cognitive impairment: imaging&#xD;
             (brain MRI) and neuropsychological assessment with a CDR scale of 0.5 - for the group&#xD;
             &quot;subjects with minor cognitive impairment&quot;.&#xD;
&#xD;
          -  Absence of cognitive problems and normal neurological assessment - for the healthy&#xD;
             group.&#xD;
&#xD;
          -  Fasting at least 2 hours before PEG measurement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - A person who is not affiliated to or not a beneficiary of a social security system.&#xD;
&#xD;
          -  Person subject to a measure of legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person subject to a judicial safeguard measure&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Adult unable to express consent or perform cognitive testing.&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  No Caregiver for Mild Alzheimer's Disease Patients&#xD;
&#xD;
          -  Active smoker&#xD;
&#xD;
          -  Diabetes (type 1 or type 2)&#xD;
&#xD;
          -  Taking a treatment that interferes with taste&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 30 kg/m2&#xD;
&#xD;
          -  MMS Score &lt;20&#xD;
&#xD;
          -  Cerebral MRI finding another cause of neurocognitive disorder (except for Fazekas 1&#xD;
             vascular lesions accepted).&#xD;
&#xD;
          -  Known COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnès JAQUIN-PIQUES</last_name>
    <phone>03 80 29 59 02</phone>
    <email>agnes.jacquin-piques@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès JACQUIN-PIQUES</last_name>
      <phone>03 80 29 59 02</phone>
      <email>agnes.jacquin-piques@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

